牛牛AI助理已提取核心訊息
On February 26, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission (SEC) by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, indicating a significant ownership stake in Altimmune, Inc. The filing, which is a requirement for parties owning more than five percent of a company's stock, shows that the entities collectively hold 2,911,937 shares of Altimmune's common stock, representing 5.4% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired the securities for investment purposes and not with the intent of changing or influencing the control of the issuer. The principal executive offices of Altimmune, Inc. are located in Gaithersburg, Maryland. The filing also includes a joint filing agreement dated March 4, 2024, confirming the collaborative nature of the filing among the reporting persons.
On February 26, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission (SEC) by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, indicating a significant ownership stake in Altimmune, Inc. The filing, which is a requirement for parties owning more than five percent of a company's stock, shows that the entities collectively hold 2,911,937 shares of Altimmune's common stock, representing 5.4% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired the securities for investment purposes and not with the intent of changing or influencing the control of the issuer. The principal executive offices of Altimmune, Inc. are located in Gaithersburg, Maryland. The filing also includes a joint filing agreement dated March 4, 2024, confirming the collaborative nature of the filing among the reporting persons.
2024年2月26日，千禧管理有限責任公司、千禧集團管理有限責任公司和以色列英格蘭德向美國證券交易委員會（SEC）提交了附表13G，表明Altimmune, Inc.擁有大量所有權。該文件要求各方擁有公司5％以上的股份，顯示這些實體共持有代表Altimmune普通股的2,911,937股股份，佔公司證券類別的5.4％。這些股份以共同的投票權和處置權持有。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，該文件供出於投資目的收購證券且無意改變或影響發行人控制權的人使用。Altimmune, Inc.的主要行政辦公室位於馬里蘭州的蓋瑟斯堡。該文件還包括一份日期爲2024年3月4日的聯合申報協議，該協議確認了申報人之間的合作性質。
2024年2月26日，千禧管理有限責任公司、千禧集團管理有限責任公司和以色列英格蘭德向美國證券交易委員會（SEC）提交了附表13G，表明Altimmune, Inc.擁有大量所有權。該文件要求各方擁有公司5％以上的股份，顯示這些實體共持有代表Altimmune普通股的2,911,937股股份，佔公司證券類別的5.4％。這些股份以共同的投票權和處置權持有。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，該文件供出於投資目的收購證券且無意改變或影響發行人控制權的人使用。Altimmune, Inc.的主要行政辦公室位於馬里蘭州的蓋瑟斯堡。該文件還包括一份日期爲2024年3月4日的聯合申報協議，該協議確認了申報人之間的合作性質。
有用
沒用